Stock vs Stock Comparison

The Cigna Group vs Eli Lilly and Company

LLY wins the Tale of the Tape 6–3.

CI$272.72
LLY$1064.15

🏆 Tale of the Tape

36
CILLY
2.2%Profitability (Net Margin)31.7%
2.4xValuation (P/E)39.2x
4.6%Efficiency (ROIC)30.4%
5/9Health (Piotroski F)7/9
2.7Safety (Altman Z)7.8
12.5%Growth (Rev YoY)44.7%
-0.38Risk (Sharpe 1Y)0.61
2.77xBalance Sheet (D/E)3.24x
8.77%FCF Yield0.68%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.056
252-Day Correlation
-0.079
126-Day Correlation

Low correlation — excellent diversification pair.

Fundamentals

MetricCILLY
Market Cap$73.4B$985.4B
P/E Ratio2.4x39.2x
Forward P/E8.3x24.8x
P/B1.74x31.65x
Dividend Yield2.25%0.63%
Beta0.310.48

Quantitative Metrics

MetricCILLY
DCF Fair Value$608.57$296.11
DCF Upside+121.2%-68.2%
Piotroski F5/97/9
Altman Z2.737.84
Beneish M-1.91
FCF Yield8.77%0.68%
Net Debt/EBITDA1.9x1.1x
ROIC4.6%30.4%
WACC6.8%7.8%
ROIC – WACC-2.2pp22.5pp
Gross Margin83.0%
Net Margin2.2%31.7%
Rev Growth YoY12.5%44.7%
Sharpe (1Y)-0.380.61
Max Drawdown 3Y
FCF Payout Ratio19%90%

CI Price

Loading chart...

LLY Price

Loading chart...

ETF Exposure

CI found in:

XHS1.94%
XLV1.39%
VHT1.26%
VFVA0.89%
ONEV0.78%
ONEO0.43%
MGV0.38%
VYM0.32%
VTV0.30%
SCHV0.26%
SPYV0.26%
QUS0.24%
VONV0.22%
IWD0.21%
RSP0.20%
ESGV0.14%
SPLG0.14%
IVV0.13%
SCHX0.12%
VONE0.12%
VOO0.12%
SCHB0.12%
SPY0.12%
ITOT0.11%
VTI0.11%
SPTM0.11%
URTH0.09%
ACWI0.07%
VT0.07%
IWF0.02%
VONG0.02%

LLY found in:

XLV15.40%
IYH13.72%
VHT12.15%
VIG3.33%
SCHG3.17%
QUAL2.92%
MGK2.82%
IWF2.66%
VONG2.42%
SPYG2.36%
VUG2.31%
IVW2.23%
QUS1.95%
XPH1.90%
ESGV1.48%
DGRW1.46%
IVV1.46%
SCHX1.34%
SPY1.29%
ITOT1.29%
SCHB1.25%
VFQY1.23%
VOO1.20%
SPTM1.20%
VTI1.14%
VONE1.14%
SPLG1.10%
ARKG1.04%
URTH0.99%
ACWI0.87%
VT0.66%
VFMO0.46%
RSP0.20%
ONEO0.02%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

CI vs LLY: Head-to-Head Analysis

The Cigna Group (CI) and Eli Lilly and Company (LLY) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, LLY leads 6–3 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, CI generates a return on invested capital (ROIC) of 4.6% compared to LLY's 30.4%. This suggests LLY is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between CI and LLY is 0.056, indicating low correlation, making them an effective diversification pair in a portfolio context.

CI appears in 31 ETFs tracked by SecuritiesDB, while LLY appears in 34 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, CI or LLY?

Our quantitative analysis compares CI and LLY across nine fundamental dimensions. LLY wins the Tale of the Tape 6–3. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are CI and LLY correlated?

The 252-day correlation between CI and LLY is 0.056. They have low correlation, offering good diversification.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.